PTPN9

Across TCGA pan-cancer cohorts, PTPN9 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PTPN9’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where PTPN9 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PTPN9 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and HNSC are the cancer types where PTPN9 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTPN9 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−0.278	<.001	9	view →
LSCC	Male	II,III,IV	−0.309	<.001	8	view →
HNSC	Male	IV	+0.289	<.001	8	view →
COAD	Male	II,III,IV	−0.203	<.001	7	view →
PDAC	All	All	+0.201	.001	5	view →
OV	All	All	−0.243	.029	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PTPN9–LUAD

Open the LUAD breakdown →